Therapeutic Strategies Targeting CD47-SIRPα Signaling Pathway in Gastrointestinal Cancers Treatment

Overview

Journal J Pharm Anal

Date 2025 Jan 30

PMID 39881799

Authors

Zhengping Che

Wei Wang

Lin Zhang

Zhenghong Lin

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal (GI) cancers are prevalent globally, with leading incidence and mortality rates among malignant tumors. Despite notable advancements in surgical resection, radiotherapy, and chemotherapy, the overall survival rates remain low. Hence, it is imperative to explore alternative approaches that enhance patient outcomes. Cluster of differentiation 47 (CD47), serving as an early diagnostic marker, is predominantly overexpressed in GI cancers and associated with poor prognosis. Targeting the CD47-signal regulatory protein alpha (SIRPα) signaling pathway may provide a novel strategy for GI cancers treatment. This study summarizes current knowledge of the structure and function of CD47 and SIRPα, their roles in signaling pathways, the prognostic significance of CD47, therapeutic strategies targeting the CD47-SIRPα signaling pathway in GI cancer, and highlights key issues for future investigations.

References

La H, Tran D, Tran H, Nguyen L . Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis. J Immunol Res. 2021; 2021:5575260. PMC: 8192203. DOI: 10.1155/2021/5575260. View

Chen C, Lu F, Huang H, Pan Y . Translating CD47-targeted therapy in gastrointestinal cancers: Insights from preclinical to clinical studies. iScience. 2024; 27(12):111478. PMC: 11667074. DOI: 10.1016/j.isci.2024.111478. View

Tsai R, Discher D . Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008; 180(5):989-1003. PMC: 2265407. DOI: 10.1083/jcb.200708043. View

Weiskopf K, Ring A, Ho C, Volkmer J, Levin A, Volkmer A . Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013; 341(6141):88-91. PMC: 3810306. DOI: 10.1126/science.1238856. View

Hsieh R, Krishnan S, Wu R, Boda A, Liu A, Winkler M . ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol. 2022; 7(72):eabl9330. PMC: 9373855. DOI: 10.1126/sciimmunol.abl9330. View

Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L . CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers (Basel). 2017; 9(10). PMC: 5664078. DOI: 10.3390/cancers9100139. View

Dong X, Fan J, Xie W, Wu X, Wei J, He Z . Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023; 129(3):551-562. PMC: 10403530. DOI: 10.1038/s41416-023-02319-6. View

Zhou Y, Qian M, Li J, Ruan L, Wang Y, Cai C . The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapy. Biomed Pharmacother. 2023; 170:116014. DOI: 10.1016/j.biopha.2023.116014. View

Lascorz J, Bevier M, V Schonfels W, Kalthoff H, Aselmann H, Beckmann J . Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer. Int J Colorectal Dis. 2012; 28(2):173-81. DOI: 10.1007/s00384-012-1541-4. View

10.

Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J . Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023; 8(1):104. PMC: 9990587. DOI: 10.1038/s41392-023-01365-z. View

11.

Lau A, Khavkine Binstock S, Thu K . CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. Cancers (Basel). 2023; 15(21). PMC: 10649163. DOI: 10.3390/cancers15215229. View

12.

Petrova P, Nielsen Viller N, Wong M, Pang X, Lin G, Dodge K . TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2016; 23(4):1068-1079. DOI: 10.1158/1078-0432.CCR-16-1700. View

13.

Huang C, Ye Z, Huang M, Lu J . Regulation of CD47 expression in cancer cells. Transl Oncol. 2020; 13(12):100862. PMC: 7494507. DOI: 10.1016/j.tranon.2020.100862. View

14.

Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J . Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer. Front Immunol. 2021; 12:768115. PMC: 8710451. DOI: 10.3389/fimmu.2021.768115. View

15.

Ye Z, Yu W, Huang M, Chen J, Lu J . Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharm Sin B. 2023; 13(4):1467-1487. PMC: 10149906. DOI: 10.1016/j.apsb.2022.12.016. View

16.

Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M . The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2008; 73(3-4):215-20. DOI: 10.1159/000127412. View

17.

Roberts D, Isenberg J . CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes. Am J Physiol Cell Physiol. 2021; 321(2):C201-C213. PMC: 8424672. DOI: 10.1152/ajpcell.00175.2021. View

18.

Tao H, Qian P, Wang F, Yu H, Guo Y . Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model. Oncol Res. 2017; 25(9):1579-1587. PMC: 7841197. DOI: 10.3727/096504017X14900505020895. View

19.

Cooney T, Wei M, Rangaswami A, Xu L, Sage J, Hazard F . CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma. Ann Clin Lab Sci. 2017; 47(4):395-402. View

20.

Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T . CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep. 2012; 28(2):465-72. DOI: 10.3892/or.2012.1831. View